Gabapentin (All indications) updated on 04-22-2025

Severe cognitive developmental delay (Mental retardation) (3-6 years old)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17408
R73019
Madley-Dowd_SE (Gabapentin) (Controls exposed to LTG) (Mixed indications), 2024 Intellectual disability (intelligence quotient below 70) - ICD-8/9/10 codes - Mean 5-20 years old (according groups) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: Yes 0.93 [0.43;2.05]
excluded (control group)
7/864   60/5,035 67 864
ref
S17411
R73037
Madley-Dowd_SE (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024 Intellectual disability (intelligence quotient below 70) - ICD-8/9/10 codes - Mean 5-20 years old (according groups) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.02 [0.49;2.15] 7/864   24,323/2,651,210 24,330 864
ref
S17410
R73031
Madley-Dowd_SE (Gabapentin) (Controls unexposed, sibling) (Mixed indications), 2024 Intellectual disability (intelligence quotient below 70) - ICD-8/9/10 codes - Mean 5-20 years old (according groups) during pregnancy (anytime or not specified) population based cohort retrospective sibling excluded Adjustment: Yes 1.91 [0.52;7.03]
excluded (control group)
-/-   -/- - -
ref
S17265
R72280
Madley-Dowd_UK (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024 Intellectual disability - ICD10 codes - Median 4.93 (3.11-7.46) years old during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 0.41 [0.03;6.51] C 0/564   1,119/514,066 1,119 564
ref
S10095
R36749
Coste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 Diagnosis Mental retardation (F70–F79) (mean age of 3.7 years old) during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No 0.25 [0.01;4.15] C
excluded (control group)
0/378   15/2,916 15 378
ref
S8517
R28094
Coste (Controls unexposed, NOS) (Mixed indications), 2020 Diagnosis Mental retardation (F70–F79) (mean age of 3.6 years old) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 0.67 [0.04;10.66] C 0/378   3,398/1,710,441 3,398 378
ref
Total 3 studies 0.94 [0.47;1.87] 28,847 1,806
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Madley-Dowd_SE (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024Madley-Dowd_SE, 2024 1 1.02[0.49; 2.15]24,33086488%ROB confusion: seriousROB selection: lowROB classification: lowROB missing: lowROB mesure: criticalROB reporting: moderate Madley-Dowd_UK (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024Madley-Dowd_UK, 2024 2 0.41[0.03; 6.51]1,1195646%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: unclearROB mesure: criticalROB reporting: moderate Coste (Controls unexposed, NOS) (Mixed indications), 2020Coste, 2020 3 0.67[0.04; 10.66]3,3983786%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 0.94[0.47; 1.87]28,8471,8060.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Gabapentin) (Controls unexposed, general pop) (Mixed indications; 2: Gabapentin) (Controls unexposed, general pop) (Mixed indications; 3: Controls unexposed, NOS) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.94[0.47; 1.87]28,8471,8060%NAMadley-Dowd_SE (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024 Coste (Controls unexposed, NOS) (Mixed indications), 2020 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.94[0.47; 1.87]28,8471,8060%NAMadley-Dowd_SE (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024 Coste (Controls unexposed, NOS) (Mixed indications), 2020 3 Tags Adjustment   - No  - No 0.52[0.07; 3.70]4,5179420%NAMadley-Dowd_UK (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024 Coste (Controls unexposed, NOS) (Mixed indications), 2020 2   - Yes  - Yes 1.02[0.49; 2.14]24,330864 -NAMadley-Dowd_SE (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024 1 All studiesAll studies 0.94[0.47; 1.87]28,8471,8060%NAMadley-Dowd_SE (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024 Coste (Controls unexposed, NOS) (Mixed indications), 2020 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 10095, 17408, 17410

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.94[0.47; 1.87]28,8471,8060%NAMadley-Dowd_SE (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024 Coste (Controls unexposed, NOS) (Mixed indications), 2020 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.85[0.40; 1.80]821,2420%NAMadley-Dowd_SE (Gabapentin) (Controls exposed to LTG) (Mixed indications), 2024 Coste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 2 siblingssiblings 1.91[0.52; 7.02]-- -NAMadley-Dowd_SE (Gabapentin) (Controls unexposed, sibling) (Mixed indications), 2024 10.510.01.0